Vascular Solutions Launches ThrombiDisc(TM) Topical Hemostat in U.S.
January 21 2014 - 8:00AM
- Novel thrombin-based topical hemostat
controls bleeding from vascular access sites -
Designed specifically for use around indwelling lines up to
12F - Contains antimicrobial properties of silver
chloride
Vascular Solutions, Inc. (Nasdaq:VASC) today announced the U.S.
market launch of ThrombiDisc topical hemostat, a thrombin-based pad
used as an adjunct to manual compression to control surface
bleeding from vascular access sites and percutaneous catheters or
tubes.
The ThrombiDisc topical hemostat is a sterile pad 1" in diameter
containing lyophilized bovine thrombin, a protein substance that
gives the bandage its bleeding control properties, and silver
chloride, which provides antimicrobial properties. A pre-formed
slit and a 4mm diameter hole in the center of the pad allow easy
placement of ThrombiDisc around indwelling lines up to 12 French in
diameter.
"Effective control of bleeding around indwelling vascular access
devices such as central venous catheters and peripherally-inserted
central catheters is a clinical imperative that ThrombiDisc was
designed specifically to meet," said Howard Root, Chief Executive
Officer of Vascular Solutions. "ThrombiDisc builds on Vascular
Solutions' long experience in the use of lyophilized bovine
thrombin as a topical hemostat in a variety of clinical settings.
While other pads placed around indwelling lines merely absorb
blood, ThrombiDisc addresses the bleeding problem with an active
ingredient. In vitro testing has demonstrated ThrombiDisc's ability
to create a much quicker clot compared to the two most popular
alternatives."
ThrombiDisc also contains the antimicrobial ingredient silver
chloride. In the presence of fluids, such as blood and wound
fluids, ionic silver is released from the silver chloride to
prevent microorganisms commonly encountered in the clinical setting
from colonizing on the pad. Ionic silver, an atom of silver that is
missing one electron, provides its antimicrobial property by
altering protein structures and preventing bacterial cells from
carrying out normal functions.
About ThrombiDisc Topical Hemostat
ThrombiDisc topical hemostat consists of a lyophilized pad
containing bovine thrombin, silver chloride, sodium
carboxymethylcellulose, and calcium chloride in a nonwoven gauze.
The 1" sterile disc is placed directly over the source of the
bleeding as an adjunct to manual compression. The pre-formed slit
and 4mm diameter hole in the ThrombiDisc allow for placement around
indwelling lines up to 12F. In vitro testing demonstrated that
representative samples of ThrombiDisc killed at least 99.99% of
seven common microbes known to cause catheter-related bloodstream
infections (CRBSIs) after 24 hours of contact. The antimicrobial
properties of ThrombiDisc have not been clinically tested, and the
in vitro test results have not been determined to correlate with a
reduction in infections. Indications: ThrombiDisc hemostatic
bandage is applied topically as an adjunct to manual compression
and is indicated for the control of surface bleeding from vascular
access sites and percutaneous catheters or tubes. ThrombiDisc
contains silver chloride to prevent microorganisms commonly
encountered in the clinical setting from colonizing on the pad.
Contraindications: ThrombiDisc is contraindicated in persons with
known sensitivity to bovine-derived materials.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company
that focuses on developing unique clinical solutions for coronary
and peripheral vascular procedures. The company's product line
consists of more than 75 products in three categories: catheter
products, hemostat products and vein products. Vascular
Solutions delivers its products to interventional cardiologists,
interventional radiologists, electrophysiologists, and vein
specialists through its direct U.S. sales force and international
independent distributor network.
The information in this press release contains forward-looking
statements that involve risks and uncertainties. Our actual results
could differ materially from those anticipated in these
forward-looking statements. Important factors that may cause such
differences include those discussed in our Annual Report on Form
10-K for the year ended December 31, 2012 and other recent filings
with the Securities and Exchange Commission. The risks and
uncertainties include, without limitation, risks associated with
the need for adoption of our new products, lack of sustained
profitability, exposure to intellectual property claims,
significant variability in quarterly results, exposure to possible
product liability claims, the development of new products by
others, doing business in international markets, the availability
of third party reimbursement, and actions by the FDA.
For further information, connect to www.vasc.com.
CONTACT: Vascular Solutions, Inc.
James Hennen, CFO
JHennen@vasc.com
(763) 656-4352
Phil Nalbone, VP-Corp. Dev.
PNalbone@vasc.com
(763) 656-4371
Vascular Solutions, Inc. (NASDAQ:VASC)
Historical Stock Chart
From Apr 2024 to May 2024
Vascular Solutions, Inc. (NASDAQ:VASC)
Historical Stock Chart
From May 2023 to May 2024